Related Experiment Videos
Alpha-interferon in hairy cell leukemia: an initial Indian experience
H Malhotra1, S H Advani, R Gopal
1Department of Medical Oncology, Tata Memorial Hospital, Parel, Bombay.
The Journal of the Association of Physicians of India
|March 1, 1992
Summary
Recombinant alpha-interferon (IFN) shows high effectiveness and good tolerability for initial hairy cell leukemia (HCL) treatment in India. IFN offers a valuable alternative to splenectomy in select cases.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hairy cell leukemia (HCL) is a rare B-cell malignancy.
- Traditional treatment involves splenectomy, but alternatives are sought.
Purpose of the Study:
- To evaluate the efficacy and tolerability of recombinant alpha-interferon (IFN) as initial therapy for HCL.
- To assess IFN as an alternative to splenectomy in Indian patients.
Main Methods:
- Retrospective analysis of 14 HCL patients diagnosed over a decade.
- Five patients received recombinant alpha-interferon (IFN) as initial treatment.
- Clinical response and side effects were monitored.
Main Results:
- Four out of five patients achieved complete remission with IFN therapy.
- One patient had a partial response; one relapsed after stopping IFN.
- Common side effects included fever and skin rash, generally manageable.
Conclusions:
- Recombinant alpha-interferon (IFN) is highly effective and well-tolerated for initial HCL treatment in India.
- IFN presents a useful alternative to splenectomy in selected HCL cases.
- Further investigation into IFN's role in HCL management is warranted.